SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): GEN1042

            Therapeutic Area: Oncology Product Name: GEN1042

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Genmab

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 23, 2020

            Details:

            Genmab together with BioNTech, has begun clinical development of an investigational therapy, GEN1042 (DuoBody®-CD40x4-1BB), for solid tumors. GEN1042 is a novel bispecific agonistic antibody targeting CD40 and 4-1BB for priming and activation of tumor-specific immune response.